Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress

International Journal of Oncology

Volumn 48, Issue 1, 2016, Pages 399-408

  Lee, Yoon Mi ^a   Lee, Gibok ^b   Oh, Taek In ^b   Kim, Byeong Mo ^c   Shim, Do Wan ^b   Lee, Kwang Ho ^b   Kim, Young Jun ^b   Lim, Beong Ou ^b   Lim, Ji Hong ^b  

^a Departments of Food Bioscience   (South Korea)

^b Konkuk University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Apigenin; Apoptosis; Cancer metabolism; NADPH; Oidative stress

Indexed keywords

APIGENIN; GLUCOSE TRANSPORTER 1; GLUTAMINE; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; BENZOPHENANTHRIDINE DERIVATIVE; COMPOUND 968; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE; SLC2A1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; DOWN REGULATION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; LUNG CANCER CELL LINE; METABOLIC STRESS; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APIGENIN; APOPTOSIS; BENZOPHENANTHRIDINES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLUTAMINE; HUMANS; LUNG NEOPLASMS; MICE; NADP; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84953239040     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3243     Document Type: Article

References (38)

1. Li-Weber M: Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett 332: 304-312, 2013.
2. Gupta SC, Kim JH, Prasad S and Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434, 2010.
3. Banerjee K and Mandal M: Oxidative stress triggered by naturally occurring flavone apigenin results in senescence and chemotherapeutic effect in human colorectal cancer cells. Redox Biol 5: 153-162, 2015.
4. Chan LP, Chou TH, Ding HY, Chen PR, Chiang FY, Kuo PL and Liang CH: Apigenin induces apoptosis via tumor necrosis factor receptor-and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta 1820: 1081-1091, 2012.
5. Kachadourian R and Day BJ: Flavonoid-induced glutathione depletion: Potential implications for cancer treatment. Free Radic Biol Med 41: 65-76, 2006.
6. Shukla S and Gupta S: Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med 44: 1833-1845, 2008.
7. Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95, 2011.
8. Vander Heiden MG: Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 10: 671-684, 2011.
9. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, et al: PGC1? expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23: 287-301, 2013.
10. Szablewski L: Expression of glucose transporters in cancers. Biochim Biophys Acta 1835: 164-169, 2013.
11. Kim MS, Kwon JY, Kang NJ, Lee KW and Lee HJ: Phloretin induces apoptosis in H-Ras MCF10A human breast tumor cells through the activation of p53 via JNK and p38 mitogen-activated protein kinase signaling. Ann NY Acad Sci 1171: 479-483, 2009.
12. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al: A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11: 1672-1682, 2012.
13. Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, et al: A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther 7: 3546-3555, 2008.
14. Hatanaka M: Transport of sugars in tumor cell membranes. Biochim Biophys Acta 355: 77-104, 1974.
15. Ulanovskaya OA, Cui J, Kron SJ and Kozmin SA: A pairwise chemical genetic screen identifies new inhibitors of glucose transport. Chem Biol 18: 222-230, 2011.
16. Patra KC and Hay N: The pentose phosphate pathway and cancer. Trends Biochem Sci 39: 347-354, 2014.
17. Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, et al: 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 4: 117-130, 1998.
18. Zhao Y, Butler EB and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4: e532, 2013.
19. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, et al: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70: 8981-8987, 2010.
20. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, et al: Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18: 207-219, 2010.
21. Lim JH, Luo C, Vazquez F and Puigserver P: Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res 74: 3535-3545, 2014.
22. Bao YY, Zhou SH, Fan J and Wang QY: Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers. Future Oncol 9: 1353-1364, 2013.
23. Bao YY, Zhou SH, Lu ZJ, Fan J and Huang YP: Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo. Oncol Rep 34: 1805-1814, 2015.
24. Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 37: 426-431, 2008.
25. Xu YY, Wu TT, Zhou SH, Bao YY, Wang QY, Fan J and Huang YP: Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: An in vitro study. Int J Clin Exp Pathol 7: 3938-3947, 2014.
26. Hamanaka RB and Chandel NS: Targeting glucose metabolism for cancer therapy. J Exp Med 209: 211-215, 2012.
27. Jeon SM, Chandel NS and Hay N: AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-665, 2012.
28. Lim JH: Zinc finger and BTB domain-containing protein 3 is essential for the growth of cancer cells. BMB Rep 47: 405-410, 2014.
29. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR and Chandel NS: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107: 8788-8793, 2010.
30. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al: Glucoseindependent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15: 110-121, 2012.
31. Wise DR and Thompson CB: Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 35: 427-433, 2010.
32. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Rémésy C, Chap H and Payrastre B: Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53: 1649-1657, 1997.
33. Fang J, Xia C, Cao Z, Zheng JZ, Reed E and Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19: 342-353, 2005.
34. Huang YT, Kuo ML, Liu JY, Huang SY and Lin JK: Inhibitions of protein kinase C and proto-oncogene expressions in NIH 3T3 cells by apigenin. Eur J Cancer 32A: 146-151, 1996.
35. Llorens F, Miró FA, Casañas A, Roher N, Garcia L, Plana M, Gómez N and Itarte E: Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. Exp Cell Res 299: 15-26, 2004.
36. Yin F, Giuliano AE, Law RE and Van Herle AJ: Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21 (1A): 413-420, 2001.
37. Adekola K, Rosen ST and Shanmugam M: Glucose transporters in cancer metabolism. Curr Opin Oncol 24: 650-654, 2012.
38. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et al: Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13: 890-901, 2014.